Industry Case Study — CS-002

Summit and Dallas Research Institute: Buying Therapeutic Depth, One Site at a Time

Published November 2026 — In September 2026, Summit Clinical Research Solutions added Dallas Research Institute, a two-year-old metabolic and liver disease site, to its Pinnacle network. The deal shows how specialist networks grow, and why a young site is hard to assess from the outside.

Executive Summary

A Specialist Network Adds a Specialist Site

On September 10, 2026, LongueVue Capital announced that its portfolio company Summit Clinical Research Solutions had acquired Dallas Research Institute (DRI) through the Pinnacle Clinical Research site network. Terms were not disclosed.

DRI is a single site in the Dallas-Fort Worth area focused on MASLD, MASH, and obesity. It was founded in 2024 as a joint venture between Summit and the late Dr. Stephen Harrison, a co-founder of Summit and Pinnacle. Summit therefore knew the site from the inside before it bought it. Most buyers do not have that advantage.

Key Findings

2024
Year DRI Was Founded

DRI began as a joint venture between Summit and Dr. Stephen Harrison, two years before the acquisition.

15
Fully Owned U.S. Sites

Summit reports 15 fully owned sites in the United States, alongside more than 110 partner sites across eight countries.

170+
Trials Since 2018

Summit says it has supported more than 85 sponsors across more than 170 trials since 2018.

3
Pinnacle Sites in Dallas-Fort Worth

Pinnacle already ran two sites in the area. DRI makes a third.

What the Deal Tells Us

This is a small transaction, and it is typical of how specialist site networks are assembled.

1

The Rationale

LongueVue's head of healthcare, Ryan Nagim, described DRI as a natural fit for the Pinnacle network because of its overlapping therapeutic focus. Summit concentrates on metabolic and liver disease, and DRI works in the same indications in a market where Pinnacle is already present.

2

The Asset Is the Investigator and the Indication

DRI's principal investigator, Dr. Pedro Castillo Jr., is staying with the site. In a single-site acquisition, the investigator, the indication, and the local patient population are most of what is being bought.

3

A Short Track Record

A site founded in 2024 has, at most, two years of study history. That is enough to show early signs of how it enrolls and retains participants, but not enough to show how it performs across many protocols or through staff changes.

4

The Insider's Advantage

Summit was a founding partner in DRI and could see its operations directly. A buyer approaching a similar site from outside would have to build the same picture from documents, registry data, and references, and would need a way to compare it with other candidates.

What Buyers of Sites Should Check

Specialist add-ons raise their own questions.

Measure Depth, Not Labels

Many sites list a therapeutic area. Depth shows in the number of studies run in the indication, enrollment achieved against target, and the patient population the site can actually reach.

Weight a Short History Carefully

With a young site, look at how complete and how well-evidenced the available data is, as well as what it shows. Thin data should lower confidence, not be read as a clean record.

Plan for Overlap

A third site in one metropolitan area adds capacity, but it may also draw on the same patients and referrers as the first two. Catchment and patient-pool data matter as much as the site's own numbers.

Conclusions

The DRI acquisition is a straightforward example of a network adding depth in its core indications, in a market it already knows, through a site it helped to create.

For other buyers, the lesson is in what Summit did not have to do. Without inside knowledge, assessing a young, single-investigator site requires verified data and a consistent way to compare it with alternatives.

Where SiteScore™ Fits

Comparing Specialist Sites on the Same Terms

SiteScore™ scores each site on one 0–100 scale. Therapeutic-area coverage and population reach sit in its market access category, and investigator experience, enrollment, and retention sit in its execution category. A Validated Score is checked against the site's own documents.

Each score also carries a separate Data Confidence measure that reflects how complete and well-evidenced the underlying data is. For a young site, that tells a buyer how much weight the score can bear.

Sources

This industry case study is based on published announcements and industry research. Figures are reported as stated in the sources below and have not been independently verified by Clinitiative. Companies named are not Clinitiative clients unless stated.

See How SiteScore™ Works

Standardized, document-verified scoring for clinical research sites, used by sponsors, sites, and investors.